India's health ministry report at odds with minister's claim that India will end TB by 2025
India's TB Prevalence Survey 2019-2021, the first of its kind in the country in 55 years, has found that tuberculosis (TB) is more prevalent in India than previously thought. In the country's annual TB report, another indicator of how well TB elimination program is performing, several flaws undermine confidence in the results and raise questions about whether government officials are deluding themselves, reports The Pharma Letter’s India correspondent.
On March 25, India's Health Minister Mansukh Mandaviya released the national TB Prevalence Survey and the country’s annual TB report.
Rife with several instances of missing data, oversight of disease types and notification discrepancies in both the documents, the damning reports has data that seems inconsistent with government statements.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze